These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21698178)

  • 1. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.
    Laine E; Chauvot de Beauchêne I; Perahia D; Auclair C; Tchertanov L
    PLoS Comput Biol; 2011 Jun; 7(6):e1002068. PubMed ID: 21698178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.
    Da Silva Figueiredo Celestino Gomes P; Panel N; Laine E; Pascutti PG; Solary E; Tchertanov L
    PLoS One; 2014; 9(5):e97519. PubMed ID: 24828813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
    Frost MJ; Ferrao PT; Hughes TP; Ashman LK
    Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
    Srikakulam SK; Bastys T; Kalinina OV
    Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.
    DiNitto JP; Deshmukh GD; Zhang Y; Jacques SL; Coli R; Worrall JW; Diehl W; English JM; Wu JC
    J Biochem; 2010 Apr; 147(4):601-9. PubMed ID: 20147452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
    Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
    Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
    Shah NP; Lee FY; Luo R; Jiang Y; Donker M; Akin C
    Blood; 2006 Jul; 108(1):286-91. PubMed ID: 16434489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis.
    Rajan V; Prykhozhij SV; Pandey A; Cohen AM; Rainey JK; Berman JN
    Br J Haematol; 2023 Sep; 202(5):960-970. PubMed ID: 35245395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.
    Fernández A; Sanguino A; Peng Z; Crespo A; Ozturk E; Zhang X; Wang S; Bornmann W; Lopez-Berestein G
    Cancer Res; 2007 May; 67(9):4028-33. PubMed ID: 17483313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A change in structural integrity of c-Kit mutant D816V causes constitutive signaling.
    Raghav PK; Singh AK; Gangenahalli G
    Mutat Res; 2018 Mar; 808():28-38. PubMed ID: 29482074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
    Lin YL; Roux B
    J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.
    Ueda S; Ikeda H; Mizuki M; Ishiko J; Matsumura I; Tanaka H; Shibayama H; Sugahara H; Takai E; Zhang X; Machii T; Kanakura Y
    Int J Hematol; 2002 Dec; 76(5):427-35. PubMed ID: 12512837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
    Foster R; Griffith R; Ferrao P; Ashman L
    J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
    Gleixner KV; Mayerhofer M; Aichberger KJ; Derdak S; Sonneck K; Böhm A; Gruze A; Samorapoompichit P; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Blood; 2006 Jan; 107(2):752-9. PubMed ID: 16189265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
    Roskoski R
    Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric communication across the native and mutated KIT receptor tyrosine kinase.
    Laine E; Auclair C; Tchertanov L
    PLoS Comput Biol; 2012; 8(8):e1002661. PubMed ID: 22927810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.
    Vendôme J; Letard S; Martin F; Svinarchuk F; Dubreuil P; Auclair C; Le Bret M
    J Med Chem; 2005 Oct; 48(20):6194-201. PubMed ID: 16190746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process.
    Zou J; Wang YD; Ma FX; Xiang ML; Shi B; Wei YQ; Yang SY
    Proteins; 2008 Jul; 72(1):323-32. PubMed ID: 18214972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
    Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
    PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
    Jin B; Ding K; Pan J
    Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.